IP Library › Granted Patent US 12,496,309
Granted Patent B2
US 12,496,309 · App. 17/852,774 · Granted Dec 16, 2025

Method for treatment of pancreatitis

Inventors: Heon Jong Lee (Incheon-si, KR); Hoe Yune Jung (Pohang-si, KR); In-Kyu Lee (Daegu, KR); Jae-Han Jeon (Daegu, KR); Sung Jin Cho (Daegu, KR); Jina Kim (Daegu, KR); Hayoung Hwang (Daegu, KR); Yong Hyun Jeon (Daegu, KR); Jungwook Chin (Daegu, KR); Dipanjan Chanda (Daegu, KR)
Assignee: NovMetaPharma Co., Ltd.
A61K31/695A61K31/396A61K31/397A61K31/40A61K31/4025A61K31/403A61K31/407A61K31/433A61K31/443A61K31/4453A61K31/454A61K31/495A61K31/5375A61P1/18
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,496,309
App. No.
17/852,774
Granted
Dec 16, 2025
Kind
B2
Abstract

A composition for preventing and/or treating pancreatitis and a method of prevention and/or treatment of pancreatitis are disclosed. The composition include an aryl ethene compound, a pharmaceutically acceptable salt thereof, or a solvate thereof, as an active ingredient. Also disclosed is a use of the aryl ethene compound, a pharmaceutically acceptable salt thereof, or a solvate thereof, in manufacturing a medicament for preventing and/or treating pancreatitis or for treating one or more symptoms of pancreatitis in a patient. The method of prevention and/or treatment of pancreatitis includes administering the aryl ethene compound, an isomer, a pharmaceutically acceptable salt thereof, or a solvate thereof, in an effective amount to a subject in need thereof.

Claims (11)

1 . A method for treating pancreatitis in a subject in need thereof or for treating one or more symptoms of pancreatitis in a subject suffering from pancreatitis, said method comprising administering, to the subject, an effective amount of a compound selected from the following compounds:

a pharmaceutically acceptable salt thereof,

wherein the one or more symptoms are abdominal pain, back pain, swollen abdomen, nausea, vomiting, fever, rapid pulse, or a combination of two or more thereof.

2 . The method of claim 1 , wherein the pancreatitis is acute pancreatitis.

3 . The method of claim 1 , wherein the pancreatitis is chronic pancreatitis.

4 . The method of claim 1 , wherein the pancreatitis is hemorrhagic pancreatitis, necrotizing pancreatitis, or hemorrhagic-necrotizing pancreatitis.

5 . The method of claim 1 , wherein the subject is a mammal.

6 . The method of claim 5 , wherein the mammal is human.

7 . The method of claim 1 , wherein the compound is (E)-5-(4-hydroxyphenyl)-5-(4-(4-isopropylpiperazin-1-yl)phenyl)-4-phenylpent-4-en-1-ol of the following chemical formula:

or a pharmaceutically acceptable salt.

8 . The method of claim 1 , wherein the effective amount is 0.01 mg/kg to 1,000 mg/kg.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 12, 2022
From: LEE, HEON JONG; JUNG, HOE YUNE; LEE, IN-KYU; JEON, JAE-HAN; CHO, SUNG JIN; KIM, JINA; HWANG, HAYOUNG; JEON, YONG HYUN; CHIN, JUNGWOOK; CHANDA, DIPANJAN
To: NOVMETAPHARMA CO., LTD.
Reel/Frame 061064/0944 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 29, 2022
From: LEE, HEON JONG; JUNG, HOE YUNE; LEE, IN-KYU; JEON, JAE-HAN; CHO, SUNG JIN; KIM, JINA; HWANG, HAYOUNG; JEON, YONG HYUN; CHIN, JUNGWOOK
To: NOVMETAPHARMA CO., LTD.
Reel/Frame 060353/0928 →
Continuity (4)
Continuation PCTIB2021055508 · Jun 22, 2021
Continuation 16908195 · Jun 22, 2020
Continuation 16908195 · Jun 22, 2020
Related Publication 20220362269A1 · Nov 17, 2022
References Cited (25)
US 6875775B2 · Sodervall et al. · 2005 [cited by applicant]
US 10934303B2 · Hwang · 2021 [cited by examiner]
US 11285226B2 · Hwang · 2022 [cited by examiner]
US 20080255089A1 · Katamreddy · 2008 [cited by applicant]
US 20190167820A1 · Hwang et al. · 2019 [cited by applicant]
US 20200078476A1 · Hwang et al. · 2020 [cited by applicant]
US 20210393583A1 · Lee et al. · 2021 [cited by applicant]
KR 101819639B1 · 2018 [cited by applicant]
WO 2016138472A1 · 2016 [cited by applicant]
WO 2018004065A1 · 2018 [cited by applicant]
Kim, J. Med. Chem. 2016, 59, 10209-10227. [cited by examiner]
Misra Trends in Endocrinology & Metabolism, Apr. 2017, vol. 28, No. 4, 2611-272. [cited by examiner]
Yoshihara Cell Metab. Apr. 12, 2016; 23(4): 622-634. [cited by examiner]
West, Solid State Chemistry and Its Applications, john Wiley & Sons, 1984. [cited by examiner]
Jordan, J Med Chem. 46(6), 883-908. [cited by examiner]
Venkatesh, J. Pharm. Sci. 89, 145-154 (2000) (p. 146, left column). [cited by examiner]
J. G. Cannon, Chapter Nineteen in Burger's Medicinal Chemistry and Drug Discovery, Fifth Edition, vol. I: Principles and Practice, Wiley-Interscience 1995, pp. 783-802, 784. [cited by examiner]
International Search Report issued Sep. 27, 2021 in International Application No. PCT/IB2021/055508. [cited by applicant]
Kim et al., “Synthesis and biological evaluation of novel 4-hydroxytamoxifen analogs as estrogen-related receptor gamma inverse agonists”, European Journal of Medicinal Chemistry, 2016, vol. 120, pp. 338-352 (15 pages t… [cited by applicant]
Lei et al., “Candidate genes mediated by estrogen-related receptor γ in pancreatic β cells”, J Biochem Mol Toxicol., Sep. 3, 2019, vol. 33, e22390, pp. 1-6 (6 pages total); https://doi.org/10.1002/jbt.22390. [cited by applicant]
Written Opinion of the International Searching Authority issued Sep. 27, 2021 in International Application No. PCT/IB2021/055508. [cited by applicant]
Yoshihara et al., “ERRγ is required for the metabolic maturation of therapeutically functional glucose-responsive β cells”, Cell Metab., 2016, vol. 23, No. 4, pp. 622-634 (23 pages total). [cited by applicant]
Misra et al., “ERRγ : a Junior Orphan with a Senior Role in Metabolism”, Trends in Endocrinology & Metabolism, 2017, vol. 28, No. 4, pp. 261-272 (12 pages total). [cited by applicant]
Kim et al., “Insights of a Lead Optimization Study and Biological Evaluation of Novel 4-Hydroxytamoxifen Analogs as Estrogen-Related Receptor γ (ERRγ) Inverse Agonists”, Journal of Medicinal Chemistry, 2016, vol. 59, pp… [cited by applicant]
Extended European Search Report dated May 23, 2024, issued in European Application No. 21828157.4. [cited by applicant]